IMMUNIZATION AGAINST BRUCELLA INFECTION VI.<i>Brucella melitensis</i>

Elberg, Sanford S.; Faunce, Kenneth

doi:10.1128/jb.73.2.211-217.1957

Cited by 97 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Brucellosis control and eradication programs largely depend on vaccines, which have been successfully used worldwide for decades. Three vaccines are used in animals: B. abortus S19 and RB51, and B. melitensis Rev.1 [50][51][52]. They provide effective protection against infection and abortion in animals.…”

Section: Proteomics-based Detection Of Brucella Spp Immunodominant Pmentioning

confidence: 99%

Proteomics of Brucella

Poetsch

Marchesini

2020

Proteomes

View full text Add to dashboard Cite

Brucella spp. are Gram negative intracellular bacteria responsible for brucellosis, a worldwide distributed zoonosis. A prominent aspect of the Brucella life cycle is its ability to invade, survive and multiply within host cells. Comprehensive approaches, such as proteomics, have aided in unravelling the molecular mechanisms underlying Brucella pathogenesis. Technological and methodological advancements such as increased instrument performance and multiplexed quantification have broadened the range of proteome studies, enabling new and improved analyses, providing deeper and more accurate proteome coverage. Indeed, proteomics has demonstrated its contribution to key research questions in Brucella biology, i.e., immunodominant proteins, host-cell interaction, stress response, antibiotic targets and resistance, protein secretion. Here, we review the proteomics of Brucella with a focus on more recent works and novel findings, ranging from reconfiguration of the intracellular bacterial proteome and studies on proteomic profiles of Brucella infected tissues, to the identification of Brucella extracellular proteins with putative roles in cell signaling and pathogenesis. In conclusion, proteomics has yielded copious new candidates and hypotheses that require future verification. It is expected that proteomics will continue to be an invaluable tool for Brucella and applications will further extend to the currently ill-explored aspects including, among others, protein processing and post-translational modification.

show abstract

Section: Proteomics-based Detection Of Brucella Spp Immunodominant Pmentioning

confidence: 99%

Proteomics of Brucella

Poetsch

Marchesini

2020

Proteomes

View full text Add to dashboard Cite

show abstract

“…The live attenuated Brucella melitensis vaccine strain Rev.1 is recognized worldwide as the best vaccine available against brucellosis in sheep and goats. 10,11,82,83…”

Section: Discussionmentioning

confidence: 99%

Vaccines for Caprine Brucellosis: Status and Prospective

Kumar¹

2016

IJVV

View full text Add to dashboard Cite

Brucellosis is an endemic world wide zoonosis, affecting both human and animals. It is caused by bacteria belonging to genus Brucella. There is host specificity in Brucella species, however selective and restricted inter species transmission is also reported causing zoonosis. In human brucellosis is mainly caused by Brucella melitensis followed by Brucella abortus. Brucella melitensis is more virulent than Brucella abortus and first to cause human brucellosis. It is responsible for caprine brucellosis and goats residing in close vicinity to human are main source of infection. This can be avoided be the use of safe and effective vaccination of goat population. There is an effective vaccine for the caprine vaccination ie. Rev.1, however it has hazardous to human, thus its use is not recommended in many of the countries. Under such circumstances development and trials of various traditional and advanced vaccines have been attempted. These have been summarized and discussed on merit and demerit basis in present paper with a possibility to obtain safe and effective vaccine against Brucella melitensis.

show abstract

“…The live vaccine B. melitensis Rev 1 (Rev 1) is currently utilized for the control of brucellosis in small ruminants. This strain was developed by Herzberg and Elberg in the mid-1950s and retains common characteristics of Brucella but is resistant to streptomycin and susceptible to penicillin G [9]. Subcutaneous or conjunctival immunization with Rev 1 confers protective immunity in small ruminants.…”

Section: Introductionmentioning

confidence: 99%

“…The inclusion of vaccination programs to improve herd resistance is generally required to control the spread of the disease. To date, Rev 1 is the best available vaccine for the prevention of B. melitensis infection in small ruminants [9] and is typically administered to young animals (3-5 months old) at 0.5-2 × 10 9 colony-forming units (CFU) subcutaneously. Although a bacteremia occurs after vaccination, it has been reported that the vaccine strain is cleared in approximately 14 weeks in goats.…”

Section: Introductionmentioning

confidence: 99%

Brucella melitensis Vaccines: A Systematic Review

Naseer,

Mo,

Olsen

et al. 2023

Agriculture

View full text Add to dashboard Cite

Background: Brucella melitensis is recognized as one of the predominant zoonotic pathogens globally. Live-attenuated vaccine Rev 1 is currently the most effective vaccine for controlling B. melitensis in small ruminants. While Brucella inactivated, nanoparticle, and subunit vaccines are less effective and require multiple doses, live-attenuated vaccines are less expensive and more efficacious. Several drawbacks are associated with the administration of current attenuated B. melitensis vaccines, including interference with serological diagnostic tests, inducing abortion in pregnant animals, shedding in milk, and zoonotic infections in humans. In this systematic review, we summarize the current literature (1970–2022) on B. melitensis vaccines and review their advantages and disadvantages in order to support the rationale for a need for new or improved small ruminant brucellosis vaccines. Methods: A systematic search was carried out in Web of Science, CAB Abstracts, and PubMed. The original articles describing the B. melitensis vaccines were included. Review articles, articles not published in English, articles that did not offer full text, editorials, correspondences, case reports, case series, diagnostic tests, duplicate publications, and other Brucella vaccines (e.g., B. abortus and B. suis) were excluded. Results: Out of 3700 studies, we identified 18 articles that evaluated B. meltensis vaccines, including recombinant B. melitensis strains (16MΔhfq, 16MΔTcfSR, M5-90ΔmanB, LVM31, M5-90ΔvjbR, 16MΔmucR, ΔznuA, M5-90Δpgm, M5-90ΔwboA), live B. melitensis strain (Rev 1), nanoparticle vaccines (B. melitensis 16M, B. melitensis OMP 31, FliC protein—Mannosylated Chitosan Nanoparticles (FliC and FliC-MCN), B. melitensis and B. abortus combined, and B. melitensis 16M nanoparticles combined with oligopolysaccharide), subunit vaccines (outer membrane vesicles or outer membrane proteins), and a DNA vaccine based on B. melitensis outer membrane proteins (Omp25 and Omp31). The results from these studies revealed that these vaccines can induce humoral and cellular responses and reduce macrophage survival. However, most of these vaccines were evaluated only in murine models, which may not accurately reflect how they work in natural hosts. Conclusions: The high prevalence of B. melitensis in humans and animals remains an issue in many parts of the world. Human brucellosis can be prevented by controlling brucellosis in livestock using vaccination and test-and-removal strategies. Prospective vaccines have limitations, including interference with serodiagnostics after vaccination, virulence in humans and animals, the requirement of booster vaccinations, and insufficient efficacy in preventing infection or abortion. Moreover, most of these vaccines have been assessed in mice models, which have failed to predict immunogenicity or efficacy in natural hosts. Because of these limitations and the re-emergence of B. melitensis worldwide with a high incidence of human infection, our review suggests a need for additional research into the molecular pathology and immunological properties of B. melitensis infection and the identification of protective epitopes or genes that would allow for the development of improved vaccines for small ruminants.

show abstract

IMMUNIZATION AGAINST BRUCELLA INFECTION VI.Brucella melitensis

Abstract: The isolation of streptomycin-dependent mutants from different Brucella was suggested by the results of Hall and Spink (1947), and de

Cited by 97 publications

References 13 publications

Proteomics of Brucella

Proteomics of Brucella

Vaccines for Caprine Brucellosis: Status and Prospective

Brucella melitensis Vaccines: A Systematic Review

Contact Info

Product

Resources

About